Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Benzinga · 1d ago
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.